Pfizer ends trial of experimental cancer drug
Pfizer Inc. said it ended an advanced trial of its experimental lung cancer drug figitumumab after an independent safety committee determined the treatment was unlikely to improve patients' survival.
Market reports suggested that Pfizer Inc. has got the approval from US FDA to expand the marketing of the cancer drug.